Navigation Links
Onyx Pharmaceuticals Reports Second Quarter 2012 Financial Results
Date:8/1/2012

SOUTH SAN FRANCISCO, Calif., Aug. 1, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the second quarter 2012. Onyx reported non-GAAP net loss of $43.6 million, or $0.68 per diluted share, for the second quarter 2012 compared to non-GAAP net loss of $27.2 million, or $0.43 per diluted share, for the same period in 2011.

"Onyx's transformation in 2012 has been remarkable, with the recent accelerated approval of Kyprolis in the United States and the continued momentum with several upcoming regulatory and data milestones," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "As part of our growth strategy, we are making important investments in developing Kyprolis across additional lines of therapy and advancing our oral proteasome inhibitor, oprozomib, to further unlock the value of our pipeline. In our kinase inhibitor franchise, Nexavar is contributing increasing cash flow and Bayer's regorafenib is under FDA priority review, setting our business up for future success globally."

On a GAAP basis, Onyx reported a net loss of $106.0 million, or $1.65 per diluted share, for the second quarter 2012 compared to $54.5 million, or $0.86 per diluted share, for the same period in 2011. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Loss."

Operating RevenueRevenue from the collaboration agreement with Bayer on Nexavar® (sorafenib) tablets net sales was $72.7 million for the second quarter 2012, an increase of 7% compared to $68.0 million for the same period in 2011. Nexavar net sales, as recorded by Bayer, excluding Japan, were $214.5 million and $206.6 million for the three months ended June 30, 2012 and 2011, respectively. Onyx and Bayer are marketing and deve
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... HILL, N.C. , May 24, 2013 /PRNewswire/ ... to the forefront of many organizations, priority list. ... and medical device sectors understand a strong ... current challenges in clinical development, market education ... effectively to create a vital bridge between an ...
(Date:5/24/2013)... 2013  BD (Becton, Dickinson and Company) (NYSE: ... that it will present at the Deutsche Bank 38 th ... at 10:40 a.m. (ET). A live webcast ... website at www.bd.com/investors and will be available for ... BD BD is a leading global medical technology ...
(Date:5/24/2013)... , May 24, 2013 /PRNewswire-iReach/ -- Phoenix Houses ... non-profit substance abuse services organization, is hosting its tenth ... Hills Hotel on June 6, 2013.  More than 300 ... funds for the adolescent residential treatment centers, family therapy, ... honor individuals whose accomplishments have positive influences on the ...
Breaking Medicine Technology:Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3
... the European League Against Rheumatism,(EULAR) Congress Demonstrates ... Rheumatoid Arthritis, LONDON, England; PHILADELPHIA, Pennsylvania and ... and Genmab A/S (CSE: GEN) announced today ... to be presented at EULAR,2007, the Annual ...
... N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCept,Corporation today ... that Azixa(TM) (MPC-6827) is effective in treating,multiple types ... a,mechanism by which MPC-6827 exerts its effects, and ... proteins known to be involved,in cancer drug resistance. ...
Cached Medicine Technology:GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA) 2GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA) 3GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA) 4GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA) 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:5/25/2013)... 25, 2013 According to world-renowned scholars, ... and powerful women that ever lived. Cleopatra’s legendary beauty ... of the most powerful men in her time. Cleopatra ... to keep her skin glowing and fresh, from her ... wax, maringa oil and cyprus grass. , Cleopatra was ...
(Date:5/25/2013)... CA (PRWEB) May 25, 2013 The Slim ... its effectiveness and results. This is due to the highly ... adhesive patches. Slim weight patch offers an extra 2 months ... loss, fitness goals and get the body you desire faster ... Patch Official Website , With Slim weight patch consumers ...
(Date:5/25/2013)... Prairie Living at Chautauqua , ... American Red Cross Blood Drive from 1:30 to 5:30 ... is located at 955 Villa Ct. in Carbondale, Illinois, ... Medicaid, who need some help to maintain their independence.. ... Andrea Arview Frey, Director of Marketing for Prairie Living. ...
(Date:5/25/2013)... DF (PRWEB) May 25, 2013 Ayurveda ... sanscrit: "knowledge or wisdom of life". While a medical science, ... the transformation of consciousness. Its fundamental philosophy is that disease ... our environment. In order to re-establish optimal health, one must ... adopt a life style which brings us back into perfect ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Superior Magnetics ... relieves pain in seconds for arthritis, tendinitis and bursitis ... alternative pain relief products announced a magnetic bracelet ... magnetic bracelet for pain relief is demonstrated at fairs ... uses 5400 Gauss magnets and has customers often report ...
Breaking Medicine News(10 mins):Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... memory, language, and other cognitive skills after bypass surgery. ... or the pump used to replace heart function during ... The findings may lead to better approaches to prevent ... receive. , The study, published in the May Annals ...
... Murad, Inc. announced today,the appointment of Fernando ... Business for Latin America. In this position, Braga ... presence in key,areas, identify prospective partners and create ... http://www.newscom.com/cgi-bin/prnh/20080519/LAM066 ), "Fernando joins the Murad ...
... Diego, California, May 19, 2008 NPS Pharmaceuticals, Inc. ... data at the annual Digestive Disease Week (DDW) Congress ... reduce dependence upon parenteral nutrition (PN) in patients with ... , The Phase 3 study evaluated two ...
... ARLINGTON HEIGHTS, Ill., May 19 Plastic,surgeons performed ... ranging from repairing dog bite wounds and birth ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080519/DC22812 ), Who ... has reconstructive,surgery changed their lives?, On average, ...
... The Epilepsy,Foundation today released important information about epilepsy and ... recent news about,Senator Edward Kennedy (D-Mass)., Senator Kennedy, ... S.,Senate, reportedly experienced a seizure on Saturday. A seizure ... One in ten Americans,will have a single seizure at ...
... smoke, chemicals boosts odds, but routine screening could ... may be at increased risk for bladder cancer and ... of California, San Francisco, researchers. , The team tested ... age was 45, and found that 93 tested ...
Cached Medicine News:Health News:Bypass not to blame for heart patients' mental decline 2Health News:Murad, Inc., Appoints Fernando Braga, Jr. as Director of International Business for Latin America 2Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 2Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 3Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 4Health News:Each Day, Plastic Surgeons Are Reconstructing Lives: Restoring Function, Improving Appearances, and Elevating Self-Esteem 2Health News:The Epilepsy Foundation Sheds Light on Seizures 2Health News:Firefighters May Face Higher Risk of Bladder Cancer 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: